BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 10530710)

  • 1. Antibody-targeted therapy for myeloid leukemia.
    Appelbaum FR
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):2-8. PubMed ID: 10530710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
    Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome.
    Matthews DC
    Leukemia; 1998 Sep; 12 Suppl 1():S33-6. PubMed ID: 9777893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
    Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
    Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse.
    Shannon-Dorcy K
    Oncol Nurs Forum; 2002 May; 29(4):E52-9. PubMed ID: 12011919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies.
    Countouriotis A; Moore TB; Sakamoto KM
    Stem Cells; 2002; 20(3):215-29. PubMed ID: 12004080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-producing human-human hybridomas. III. Derivation and characterization of two antibodies with specificity for human myeloid cells.
    Andreasen RB; Olsson L
    J Immunol; 1986 Aug; 137(3):1083-90. PubMed ID: 3459756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical trial of serotherapy in patients with acute myeloid leukemia with an immunoglobulin M monoclonal antibody to CD15.
    Ball ED; Selvaggi K; Hurd D; Herzig R; Clark L; Malley V; Persichetti J; deMagelhaus-Silverman M
    Clin Cancer Res; 1995 Sep; 1(9):965-72. PubMed ID: 9816068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical evaluation of anti-lacto-N-fucopentaose III (CD15) monoclonal antibodies for ex vivo bone marrow purging in acute myeloid leukemia.
    Guyotat D; Shi ZH; Campos L; Rabat M; Bonnier S; Poncelet P; Laurent JC; Fiere D
    Bone Marrow Transplant; 1990 Dec; 6(6):385-90. PubMed ID: 1982926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunoconjugates in acute leukemia treatment: the future is radiant.
    Kotzerke J; Bunjes D; Scheinberg DA
    Bone Marrow Transplant; 2005 Dec; 36(12):1021-6. PubMed ID: 16247432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody.
    Matthews DC; Badger CC; Fisher DR; Hui TE; Nourigat C; Appelbaum FR; Martin PJ; Bernstein ID
    Cancer Res; 1992 Mar; 52(5):1228-34. PubMed ID: 1531324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.
    Feldman E; Kalaycio M; Weiner G; Frankel S; Schulman P; Schwartzberg L; Jurcic J; Velez-Garcia E; Seiter K; Scheinberg D; Levitt D; Wedel N
    Leukemia; 2003 Feb; 17(2):314-8. PubMed ID: 12592328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.
    Nguyen DH; Ball ED; Varki A
    Exp Hematol; 2006 Jun; 34(6):728-35. PubMed ID: 16728277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mylotarg approved for patients with CD33+ acute myeloid leukemia.
    Sorokin P
    Clin J Oncol Nurs; 2000; 4(6):279-80. PubMed ID: 11899326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody therapy in acute myeloid leukemia.
    Feldman EJ
    Curr Hematol Rep; 2003 Jan; 2(1):73-7. PubMed ID: 12901157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current uses of monoclonal antibodies in the treatment of acute leukemia.
    Ruffner KL; Matthews DC
    Semin Oncol; 2000 Oct; 27(5):531-9. PubMed ID: 11049021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia.
    Amadori S; Stasi R
    Curr Opin Hematol; 2008 Mar; 15(2):95-100. PubMed ID: 18300754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.